Optimizing Use of BTK Inhibitors in CLL/SLL and MCL for Managed Care Professionals

This interactive webinar will provide expert perspectives on recent advances in the use of BTK inhibitors for the personalized care of patients with CLL/SLL and MCL, including discussions about the optimal strategies to promote equitable, evidence-based quality care to ensure a cost-effective integration of BTK inhibitors into managed care decision-making. After the workshop, download the associated slideset for use in your practice. 

Share

Program Content

Activities

BTKi in CLL, SLL, and MCL
Optimizing Use of BTK Inhibitors in CLL/SLL and MCL for Managed Care Professionals
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 11, 2024

View Activity

Faculty

cover img faculity

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

cover img faculity

Victoria R. Nachar, PharmD, BCOP

Clinical Pharmacist Specialist
Hematology
University of Michigan Rogel Cancer Center 
Ann Arbor, MI

Provided by

ProCE Banner

Provided by ProCE, LLC

Supporters

This activity is supported by an educational grant from Lilly.

Lilly